BCG therapy is associated with a high frequency of side effects in NMIBC; however, when used in sequential combination with ...

Increasing the available supply of BCG is intended to address shortages for the combination ... BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without ...

BCG is also used as a biotherapy for superficial bladder carcinoma. Despite being the most successful cancer biotherapy, the mechanism of action and determinants of response to BCG remain obscure. We ...

“Bladder cancer is a large area of medical need, particularly in patients where BCG has failed,” said Vijay Kasturi, MD, Senior Vice President, Scientific Affairs. “There have been few ...

25% of bladder cancer patients are diagnosed ... a majority of the clinical effectiveness. ・Secondly, BCG is experiencing a global shortage, prompting ImmunityBio to partner with the Serum ...

aims to address the shortage of BCG. Price Action: IBRX stock is up 18.6% at $2.835 at last check Thursday.

BCG unresponsive non-muscle invasive bladder cancer (NMIBC ... aims to address the shortage of BCG, ensuring a reliable supply for patients in need. This initiative underscores ImmunityBio's ...

[JONAH ONYANGO/STANDARD.] A nationwide shortage of Bacillus Calmette-Guerin (BCG) vaccines in the country leaves Kenyan newborns vulnerable to Tuberculosis (TB), a disease with a high prevalence ...

ImmunityBio achieved a 55% disease-free rate at 12 months for BCG-unresponsive NMIBC and plans an sBLA submission in 2025. NSCLC Phase 2b trial (N=86) showed a median overall survival of 14.1 ...